newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - ABCELLERA BIOLOGICS INC

  • Financial Performance:

    • The company reports approximately $900 million in liquidity, with potential additional value from owned real estate assets.
    • The transition in 2023 involved ramping down a "hired gun" discovery service business to fund the internal portfolio, resulting in a shift from service revenue to asset value appreciation.
    • No specific quarterly revenue or profit figures were disclosed as the company is in clinical development with no commercial sales yet.
  • Guidance and Future Outlook:

    • Lead asset ABCL635 is poised to enter late-stage Phase III studies in mid-2024, following a successful Phase II readout in August.
    • Regulatory discussions with the FDA, EMA, and other jurisdictions are already underway to align on the Phase III development plan.
    • Commercial launch strategy targets a direct-to-consumer (DTC) or telehealth model, potentially alongside traditional prescriber channels, depending on final pricing strategies.
    • Full commercialization is viewed as a standalone operation for now, though partnership opportunities on the commercial side remain under evaluation.
  • Business Segments and Product Lines:

    • ABCL635: First-in-class antibody antagonist of NK3R for non-hormonal treatment of vasomotor symptoms (hot flashes) in menopause and androgen deprivation therapy; Phase II data showed double the efficacy in frequency and 4-5x in severity compared to approved small molecules.
    • ABCL635-992: A half-life-extended analog of ABCL635 engineered to achieve once-quarterly dosing, intended to protect market share and reduce cost of goods.
    • Pipeline: Two IND-enabling programs (ABCL-688 and ABCL-386) targeting clinics in 2024; additional undisclosed oncology program (ABCL-385) and a first-in-class ion channel antagonist (ABCL-646).
    • Discovery Platform: Internal platform focused on difficult targets including GPCRs, ion channels, and T-cell engagers, previously utilized via partnership models.
  • Market and Competitive Landscape:

    • The primary market is vasomotor symptoms (VMS) driven by menopause and hormone deprivation in breast and prostate cancer; current standard of care includes small molecule NK3R antagonists (e.g., Brisdelle, Lonqura) and off-label SSRIs/Gabapentin.
    • Management asserts ABCL635's efficacy vastly exceeds current non-hormonal options and stands "at least equal if not better" to hormonal treatments.
    • Patent life for ABCL635 is estimated at just under 20 years; competitors face high barriers due to the company's aggressive IP protection on the antibody and formulation.
    • Potential for head-to-head studies is acknowledged but deemed unnecessary for initial registrational Phase III trials, which will likely be placebo-controlled.
  • Risks and Challenges:

    • CMC Complexity: Scaling manufacturing and securing auto-injector/pre-filled syringe devices to support commercialization is the primary logistical hurdle alongside regulatory alignment.
    • Safety Signals: While liver toxicity (a known issue with small molecules) was not observed, mild transient headaches occurred in ~2x the rate of placebo during Phase I/II; long-term safety and headache frequency upon re-dosing remain key monitoring points.
    • Competitive Response: Management anticipates competitors may attempt to launch half-life-extended versions of the same mechanism, requiring speed-to-market and robust IP defense.
    • Pricing and Access: Uncertainty exists regarding pricing power and reimbursement strategies in a DTC vs. payer-driven model.
  • Management Commentary and Tone:

    • Tone is highly confident and optimistic, describing Phase II data as having "blew the doors off" and the efficacy as "knocking people's socks off."
    • Management emphasizes the platform's unique ability to solve "difficult challenges" in antibody discovery that other companies cannot.
    • Carl Hansen (CEO) projected a "redefinition" of non-hormonal treatment for hot flashes, citing complete symptom resolution in 37% of patients and 90% resolution in 60% of patients at four weeks.
  • Analyst Questions and Answers:

    • Q: How to interpret the 12-week washout data?
      • A: Efficacy is expected to wane by week 12 as the drug clears (half-life ~30 days); this is expected and not a negative indicator. The 12-week data serves to model exposure-response and de-risk anti-drug antibodies, not to prove long-term efficacy without re-dosing.
    • Q: What if 4-week efficacy is lower than August's data?
      • A: Management sets a high bar; any efficacy significantly superior to small molecules (e.g., 50-75% better) would still be acceptable, though they anticipate maintaining or exceeding the 4-week results.
    • Q: Liver toxicity concerns?
      • A: Confirmed that liver signals associated with small molecules are metabolic; the antibody mechanism does not exhibit this, and no liver toxicity was observed in Phase II.
    • Q: Cancer-related VMS timeline?
      • A: Breast cancer trials may move to late stage quickly due to existing data support; prostate cancer may require an additional Phase II study to establish efficacy in that specific population.
  • Other Key Points:

    • The Phase II study utilized a single 600mg dose to mimic steady-state exposure, utilizing a tight temporal correlation between target engagement and efficacy for model-informed drug development.
    • Formulation is stable at 150 mg/mL in a 2mL volume (300mg total dose), compatible with current pre-filled syringe and auto-injector technologies.
    • The company views the oncology VMS market as a significant, often overlooked opportunity parallel to the menopause market.
    • Management explicitly stated they are "fully committed" to advancing ABCL635 and ABCL635-992 internally, aiming to prove the platform's ability to invent, develop, and commercialize breakthrough medicines repeatedly.
Company
ABCELLERA BIOLOGICS INC
Keywords
ABCELLERA BIOLOGICS INC